TVTX

TVTX R&D to Revenue

41.98%Fiscal year

Period ending:

TVTX FY R&D/Revenue%
TVTX FY R&D/Revenue232.61%-24.92%
2009-02-282025-12-31

Source: Financial Modeling Prep (FMP). Annual fiscal periods. Dates are period ends; a fiscal year may differ from a calendar year.

TVTX r&d to revenue history

R&D spending as percentage of revenue. The available annual fiscal periods series contains 18 observations from Feb 28, 2009 to Dec 31, 2025.

Travere Therapeutics Inc R&D to Revenue — Annual fiscal periods
Period endingR&D to Revenue
41.9807%
121.2398%
168.6817%
207.6859%
152.5828%
66.4443%
80.395%
75.3486%
50.4515%
53.0373%
50.4805%
169.4673%
0%
0%
0%
0%
0%
0%

Compare r&d to revenue

All TVTX financial metrics · TVTX stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.